Global Celecoxib Market Insights and Forecast to 2027

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.

Market Analysis and Insights: Global Celecoxib Market
The global Celecoxib market is valued at US$ 1135 million in 2019. The market size will reach US$ 1902.8 million by the end of 2026, growing at a CAGR of 8.4% during 2021-2026.

Global Celecoxib Scope and Market Size
Celecoxib market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Celecoxib market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
50mg
100mg
200mg
400mg

Segment by Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases

By Company
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia